Dasiglucagon Effectively Mitigates Postbariatric Postprandial Hypoglycemia: A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › fagfællebedømt

Standard

Dasiglucagon Effectively Mitigates Postbariatric Postprandial Hypoglycemia : A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial. / Nielsen, Casper K; Øhrstrøm, Caroline C; Kielgast, Urd L.; Hansen, Dorte L.; Hartmann, Bolette; Holst, Jens J; Lund, Asger; Vilsbøll, Tina; Knop, Filip K.

I: Diabetes Care, Bind 45, Nr. 6, 2022, s. 1476–1481.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › fagfællebedømt

Harvard

Nielsen, CK, Øhrstrøm, CC, Kielgast, UL, Hansen, DL, Hartmann, B, Holst, JJ, Lund, A, Vilsbøll, T & Knop, FK 2022, 'Dasiglucagon Effectively Mitigates Postbariatric Postprandial Hypoglycemia: A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial', Diabetes Care, bind 45, nr. 6, s. 1476–1481. https://doi.org/10.2337/dc21-2252

APA

Nielsen, C. K., Øhrstrøm, C. C., Kielgast, U. L., Hansen, D. L., Hartmann, B., Holst, J. J., Lund, A., Vilsbøll, T., & Knop, F. K. (2022). Dasiglucagon Effectively Mitigates Postbariatric Postprandial Hypoglycemia: A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial. Diabetes Care, 45(6), 1476–1481. https://doi.org/10.2337/dc21-2252

Vancouver

Nielsen CK, Øhrstrøm CC, Kielgast UL, Hansen DL, Hartmann B, Holst JJ o.a. Dasiglucagon Effectively Mitigates Postbariatric Postprandial Hypoglycemia: A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial. Diabetes Care. 2022;45(6):1476–1481. https://doi.org/10.2337/dc21-2252

Author

Nielsen, Casper K ; Øhrstrøm, Caroline C ; Kielgast, Urd L. ; Hansen, Dorte L. ; Hartmann, Bolette ; Holst, Jens J ; Lund, Asger ; Vilsbøll, Tina ; Knop, Filip K. / Dasiglucagon Effectively Mitigates Postbariatric Postprandial Hypoglycemia : A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial. I: Diabetes Care. 2022 ; Bind 45, Nr. 6. s. 1476–1481.

Bibtex

@article{8104d825b1324b03a20099823cc26605,
title = "Dasiglucagon Effectively Mitigates Postbariatric Postprandial Hypoglycemia: A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial",
abstract = "OBJECTIVE: To investigate the efficacy and safety of dasiglucagon, a novel stable glucagon analog in a liquid formulation, in Roux-en-Y gastric bypass (RYGB)-operated individuals suffering from postbariatric hypoglycemia (PBH).RESEARCH DESIGN AND METHODS: In a randomized, double-blind, placebo-controlled, crossover trial, 10 RYGB-operated participants with continuous glucose monitoring-verified PBH were randomly assigned to 3 trial days, each consisting of a 240-min standardized liquid mixed-meal test with the subcutaneous injection of placebo or 80 μg or 200 μg dasiglucagon.RESULTS: Compared with placebo, treatment with both 80 and 200 µg dasiglucagon raised nadir plasma glucose (PG) (placebo: 3.0 ± 0.2 mmol/L [mean ± SEM]; 80 μg dasiglucagon: 3.9 ± 0.3 mmol/L, P = 0.002; 200 μg dasiglucagon: 4.5 ± 0.2 mmol/L, P = 0.0002) and reduced time in hypoglycemia (PG <3.9 mmol/L) by 70.0 min (P = 0.030 and P = 0.008).CONCLUSIONS: Single-dose administration of dasiglucagon effectively mitigated postprandial hypoglycemia.",
author = "Nielsen, {Casper K} and {\O}hrstr{\o}m, {Caroline C} and Kielgast, {Urd L.} and Hansen, {Dorte L.} and Bolette Hartmann and Holst, {Jens J} and Asger Lund and Tina Vilsb{\o}ll and Knop, {Filip K}",
note = "{\textcopyright} 2022 by the American Diabetes Association.",
year = "2022",
doi = "10.2337/dc21-2252",
language = "English",
volume = "45",
pages = "1476–1481",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association",
number = "6",

}

RIS

TY - JOUR

T1 - Dasiglucagon Effectively Mitigates Postbariatric Postprandial Hypoglycemia

T2 - A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial

AU - Nielsen, Casper K

AU - Øhrstrøm, Caroline C

AU - Kielgast, Urd L.

AU - Hansen, Dorte L.

AU - Hartmann, Bolette

AU - Holst, Jens J

AU - Lund, Asger

AU - Vilsbøll, Tina

AU - Knop, Filip K

N1 - © 2022 by the American Diabetes Association.

PY - 2022

Y1 - 2022

N2 - OBJECTIVE: To investigate the efficacy and safety of dasiglucagon, a novel stable glucagon analog in a liquid formulation, in Roux-en-Y gastric bypass (RYGB)-operated individuals suffering from postbariatric hypoglycemia (PBH).RESEARCH DESIGN AND METHODS: In a randomized, double-blind, placebo-controlled, crossover trial, 10 RYGB-operated participants with continuous glucose monitoring-verified PBH were randomly assigned to 3 trial days, each consisting of a 240-min standardized liquid mixed-meal test with the subcutaneous injection of placebo or 80 μg or 200 μg dasiglucagon.RESULTS: Compared with placebo, treatment with both 80 and 200 µg dasiglucagon raised nadir plasma glucose (PG) (placebo: 3.0 ± 0.2 mmol/L [mean ± SEM]; 80 μg dasiglucagon: 3.9 ± 0.3 mmol/L, P = 0.002; 200 μg dasiglucagon: 4.5 ± 0.2 mmol/L, P = 0.0002) and reduced time in hypoglycemia (PG <3.9 mmol/L) by 70.0 min (P = 0.030 and P = 0.008).CONCLUSIONS: Single-dose administration of dasiglucagon effectively mitigated postprandial hypoglycemia.

AB - OBJECTIVE: To investigate the efficacy and safety of dasiglucagon, a novel stable glucagon analog in a liquid formulation, in Roux-en-Y gastric bypass (RYGB)-operated individuals suffering from postbariatric hypoglycemia (PBH).RESEARCH DESIGN AND METHODS: In a randomized, double-blind, placebo-controlled, crossover trial, 10 RYGB-operated participants with continuous glucose monitoring-verified PBH were randomly assigned to 3 trial days, each consisting of a 240-min standardized liquid mixed-meal test with the subcutaneous injection of placebo or 80 μg or 200 μg dasiglucagon.RESULTS: Compared with placebo, treatment with both 80 and 200 µg dasiglucagon raised nadir plasma glucose (PG) (placebo: 3.0 ± 0.2 mmol/L [mean ± SEM]; 80 μg dasiglucagon: 3.9 ± 0.3 mmol/L, P = 0.002; 200 μg dasiglucagon: 4.5 ± 0.2 mmol/L, P = 0.0002) and reduced time in hypoglycemia (PG <3.9 mmol/L) by 70.0 min (P = 0.030 and P = 0.008).CONCLUSIONS: Single-dose administration of dasiglucagon effectively mitigated postprandial hypoglycemia.

U2 - 10.2337/dc21-2252

DO - 10.2337/dc21-2252

M3 - Journal article

C2 - 35320361

VL - 45

SP - 1476

EP - 1481

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 6

ER -

ID: 301823969